Benign and Time-Limited Visual Disturbances (Flashbacks) in Recent Abstinent High-Potency Heavy Cannabis Smokers: a Case Series Study

Total Page:16

File Type:pdf, Size:1020Kb

Benign and Time-Limited Visual Disturbances (Flashbacks) in Recent Abstinent High-Potency Heavy Cannabis Smokers: a Case Series Study Isr J Psychiatry Relat Sci - Vol 48 - No.1 (2011) ARTURO G. LERNER ET AL. Benign and Time-Limited Visual Disturbances (Flashbacks) in Recent Abstinent High-Potency Heavy Cannabis Smokers: A Case Series Study Arturo G. Lerner, MD,1,2 ,Craig Goodman, PhD, 1 Dmitri Rudinski, MD, 1 and Avi Bleich, MD1, 2 1 Lev Hasharon Mental Health Medical Center, Pardessya, Israel 2 Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel may induce a state of intoxication popularly referred ABSTRACT to as a “trip” (4). These “trips” or substance-induced experiences are generally transient and reversible states Eight high-potency heavy cannabis smokers who that are typically accompanied by perceptual distur- fulfilled DSM-IV-TR criteria for cannabis dependence bances. The mind-altering effects are experienced in sought treatment for outpatient detoxification. a clear sensory-conscious state, while awake and alert During routine psychiatric interview they reported the and generally in the absence of confusion (5-8). A well presence of visual disturbances when intoxicated and known, unique and intriguing side effect associated no prior history of LSD use. They all communicated with the use of synthetic hallucinogens such as lysergic the persistence of visual disturbances after ceasing acid diethylamide-LSD and LSD-like substances is the cannabis use. Seven categories of visual disturbances partial or total recurrence of the perceptual disturbances were described when staring at stationary and moving which previously appeared during intoxication, in the objects: visual distortions, distorted perception of absence of recent use (9-11). These experiences are distance, illusions of movement of stationary and accompanied by full insight and can be short or long- moving objects, color intensification of objects, term (10, 11). The original intoxicating experience may dimmed color, dimensional distortion and blending be “good” (pleasant) or “bad” (unpleasant). In the same of patterns and objects. Patients reported having 2-5 way, the perceptual recurrences recapitulate the prior different categories of flashbacks up to 3-6 months “trip” or intoxication that was experienced as either after cessation of cannabis use. The described “good” or “bad.” A previous “good” trip, however, does phenomena may be interpreted as a time-limited not always predict or ensure a “good” recurrence (10, benign side effect of high-potency cannabis use in 11). Common recurrent visual disturbances attributed some individuals. A combination of vulnerability and to this complex syndrome are geometric hallucina- use of large amounts of high–potency cannabis seem tions, false perception of movement in the peripheral to contribute to the appearance of this condition. visual fields, flashes of colors, intensified colors, trails Conclusions from uncontrolled case series should be of images of moving objects, positive afterimages, halos taken with appropriate caution. around objects, macropsia and micropsia (12). At least two subtypes of this syndrome have been reported. The first is flashback. It is a short term, tran- sient, recurrent, spontaneous, reversible and generally visual benign experience. Experienced LSD users gener- INTRODUctiON ally look at these recurrences as a “free trip,” an aspect Hallucinogens encompass a group of naturally-occur- of the psychedelic dimension, and do not seek psychiat- ring substances from vegetable (1) and animal (2) ric assistance after experiencing these types of episodes. origins as well as synthetic chemical agents (3) which Certain individuals may experience the recurrence of Address for Correspondence: Arturo G. Lerner, MD, Lev Hasharon Mental Health Medical Center, POB 90000, Netanya 42100, Israel [email protected] ; [email protected] 25 BENIGN AND TIMe-LIMITED VISUAL DISTURBANCES (FlashbacKS) IN RECENT ABSTINENT HIGH-PoTENCY the same single flashback while other perhaps more attempted to stop cannabis use in the past without suggestible subjects may have a variety of them. The professional assistance. Patients included in the report second is hallucinogen persisting perception disorder met the DSM-IV-TR criteria for cannabis dependence (HPPD). This is long-term, spontaneous, intermittent (12). They reported the need for markedly increased or continuous, pervasive and either slowly reversible amounts of cannabis to achieve desired effect, cannabis or irreversible. This disorder is entirely different from was smoked over longer periods than was intended, the benign flashback (10, 11). HPPD is a condition in there were unsuccessful efforts to stop or control its which the re-experiencing of one or more perceptual use, a great deal of time was spent to obtain cannabis symptoms causes significant distress or impairment in and finally social, occupational and recreational activi- social, occupational or other important areas of func- ties were impaired (12).They communicated cannabis tioning (12). HPPD often occurs in individuals with no intoxication with perceptual disturbances (12), the prior psychopathology, and may be extremely debili- intake of high concentrated cannabis (22) since start- tating. Hallucinogen users are usually aware of these ing cannabis use, a smoking period of at least five years severe, intruding and disabling consequences of LSD and a daily consumption (“joints” and water pipes) of consumption and generally actively seek psychiatric at least three times a day (i.e., morning, noon or after- help. HPPD seems to be part of a large spectrum of noon and evening). They had no prior use of LSD or non-psychopathological and psychopathological expe- other hallucinogenic substances. All patients had pre- riences reported by hallucinogen users (10, 11). vious compulsory military service, no prior police or Whether or not the use of cannabis alone can be asso- criminal records, and were not married. Four of the ciated with persisting perceptual abnormalities has been patients reported smoking cannabis alone. The other debated. Investigators tend to agree that cannabis can four reported occasional use of cocaine, MDMA, and precipitate perceptual recurrences in subjects who had also fulfilled full criteria for nicotine dependence (12). previously used LSD and that it is unlikely that canna- Visual disturbances during intoxication were reported bis alone can provoke recurrent perceptual disturbances only after being interviewed for treatment and were not (13-15). However, there are reports of depersonalization accurately recalled. Treatment was not sought due to (16, 17), perceptual symptoms experienced during can- visual disturbances. They associated the precipitation nabis intoxication (18, 19) and short-term spontaneous of visual disturbances only and strictly by cannabis recurrent visual disturbances (20) after the suspension smoking. Other consumed legal (nicotine and alco- of cannabis use alone. Reliability of recurrent canna- hol) and illegal (ecstasy and cocaine) substances were bis associated visual experiences has been critically not associated with the perceptual disturbances. None questioned. It should be noted that according to DSM- of the patients had any co-morbid medical disease or IV-TR the diagnostic criteria of cannabis intoxication co-occurring psychiatric disorders. Neurological and allows for a diagnosis of “with perceptual disturbances” ophthalmologic examinations were intact. Two patients (12). If perceptual disturbances can be observed dur- had a family history of schizophrenia. ing intoxication by cannabis alone (12, 21), it is plau- sible that some predisposed and susceptible cannabis DEMOGRAPHIC Data heavy smokers using high concentrated cannabis (22) Mean age of patients was 29.25 years old (S.D.=2.25), may partially or totally recapitulate the previous per- mean education was 13.13 years (S.D.=1.55), mean ceptual experience in the absence of present cannabis duration of non-use was 82.25 days (S.D.=40.6), mean use. We present the cases of eight high-potency heavy duration of cannabis use was seven years (S.D.=1.69), users of cannabis without a prior history of LSD use and mean number of previous attempts of cessation or who reported the presence of benign persisting visual detoxifications was 0.625 (S.D.=0.74). All patients were disturbances after stopping cannabis consumption. white males of Jewish Israeli descent, were currently employed, and had a middle class socioeconomic status. METHOD DETOXIFicatiON AND FOLLow-up CLINicaL Data Tetrahydrocannabinol (THC) was present in urine Eight patients were examined after seeking treatment samples prior to initiation of detoxification. No other for cessation of chronic cannabis use. Four of them psychoactive substances were identified. All patients 26 ARTURO G. LERNER ET AL. underwent uncomplicated outpatient cannabis detoxi- when staring at stationary and moving objects: visual fication using only minimal symptomatic medication distortion (slightly blurred object), distorted perception like small doses of clonidine (23) and careful use of of distance (objects were slightly seen closer or distant), benzodiazepines. They continued working when under- illusion of movement of stationary and moving objects going treatment reflecting low severity or control of the (slow movement), color intensification of objects (slightly detoxification process. After detoxification and follow- more intensified), dimmed color (slightly less intensified), up, substances of abuse were not identified in random dimensional distortion (objects were slightly
Recommended publications
  • Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
    6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder.
    [Show full text]
  • Medical Cannabis Q&A
    Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence.
    [Show full text]
  • Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
    NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16.
    [Show full text]
  • Bill Analysis and Fiscal Impact Statement
    The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • (A-9-THC) Content in Herbal Cannabis Over Time
    32 Current Drug Abuse Reviews, 2012, 5, 32-40 Increasing Delta-9-Tetrahydrocannabinol (-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis Fidelia Cascini*,1, Carola Aiello2 and GianLuca Di Tanna3 1Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy 2Department of Informatics and Systemics, University ‘La Sapienza’, 00185 Rome, Italy 3Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy Abstract: Aim: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009). Methods: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review. Results: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis).
    [Show full text]
  • Endocannabinoid Stimulated Release of Nitric Oxide and Its Mitochondrial
    A tica nal eu yt c ic a a m A r a c t Stefano et al., Pharm Anal Acta 2015, 6:6 h a P Pharmaceutica Analytica Acta DOI: 10.4172/2153-2435.1000378 ISSN: 2153-2435 Review Article Open Access Endocannabinoid Stimulated Release of Nitric Oxide and its Mitochondrial Influence Triggering Vascular Pathology George B Stefano*, Erin Quinn and Richard M Kream MitoGenetics LLC, 3 Bioscience Park Drive, Suite 307, Farmingdale, NY 11735, USA Abstract Endocannabinoids, and their respective receptors, are involved in a host of cellular regulatory activities. In part, some of these mediated effects occur by way of stimulating constitutive nitric oxide release. This occurs in endothelia, certain white blood cells, microglia, and in similar invertebrate tissues, demonstrating that this is a conserved chemical messenger system. This endocannabinoid chemical messenger system, coupled to constitutive nitric oxide release, also appears to exert regulatory effects on mitochondrial energy associated processes, further substantiating its primordial history. In this regard, it appears to offer some beneficial actions in the occurrence of reperfusion injury and stroke. The mechanism envisioned is one initiated via a hypoxic event, which does not restore normalcy, then progresses to a pro-inflammatory state, and the resultant chronic condition manifests itself in a specific disorder. This fits nicely into a vascular-associated origin for Alzheimer’s Disease, whereby the pro- inflammatory state encompasses vessels that have endothelial gaps, providing for a compromised blood brain barrier, beta amyloid deposition, and enhanced white blood cell trafficking. In time, due to the physical progression of the events, Alzheimer’s Disease occurs.
    [Show full text]
  • Synthetic Cannabis
    Global emergence of synthetic cannabinoids Source: https://www.unodc.org/LSS/SubstanceGroup/Details/ae45ce06-6d33-4f5f-916a- e873f07bde02 Source: UNODC questionnaire on NPS, 2012 Background The appearance of ‘herbal highs’ in the market is not a new phenomenon. Such products usually consisted of plant mixtures with little psychoactive effects. Since 2004, however, the composition of these herbal products seems to have substantially changed to include potent new psychoactive compounds known as synthetic cannabinoids. Research on the mechanism of cannabis activity dates back several decades when molecules with similar behaviour to Δ9-tetrahydrocannabinol (THC) were first examined. A synthetic analogue of THC , ‘HU-210’, was first synthesized in Israel in 1988[1]and is considered to have a potency of at least 100 times more than THC. Due to its similar chemical structure to THC, ‘HU-210’ is regarded as a ‘classical cannabinoid’ and has been found in synthetic cannabinoids sold in the United States and other countries. Non-classical cannabinoids include cyclohexylphenols or 3-arylcyclohexanols (‘CP’compounds). ‘CP’ compounds were developed as potential analgesics by a pharmaceutical company in the 1980s. Respondents to the UNODC questionnaire on NPS have reported the emergence of CP-47,497 and CP-47,497-C8 in numerous countries in all regions except Africa since 2009. Other structurally dissimilar varieties of synthetic cannabinoids unrelated to THC have also emerged on the market. These include aminoalkylindoles, such as naphthoylindoles (e.g. JWH-018), phenylacetylindoles (e.g. JWH-250), and benzoylindoles (e.g. AM-2233).[2] JWH-018, arguably the most widely known synthetic cannabinoid, belongs to the group of aminoalkylindoles and is considered to be three times as potent as THC.
    [Show full text]
  • Understanding Synthetic Cannabis: Who Uses It, Why Do They Use It, What Are the Harms and What Are the Policy Options?
    Understanding Synthetic Cannabis: Who uses it, why do they use it, what are the harms and what are the policy options? Stephen Bright 1,2, Monica Barratt 3 1. Peninsula Health 2. School of Psychology and Speech Pathology, Curtin University 3. National Drug Research Institute, Curtin University Background 2004: “Spice” (Deluca et al., 2010) Synthetic Cannabinoid Agonists ∆9-Tetrahydracannabinol (THC) JWH-018 Kronic 2011: Kronic emerged as a new drug in Australia Produced in New Zealand Who Uses Synthetic Cannabis? Survey of 316 Australian synthetic cannabis users in 2011 - 77% male (Barratt, Cakic & Lenton, 2013) - Median age of 27 - 78% were employed “Won’t somebody think - 96% had used cannabis VS about the children?” - Extensive Drug Histories (Maude Flanders, The Simpsons) Other drug use Extensive drug histories – Alcohol (98%), Cannabis (96%), Tobacco (91%), Ecstasy (64%), LSD (57%), Speed (56%), Mushrooms (41%), Cocaine (38%), Valium (35%) More common drugs used in past year – Alcohol (91%), Cannabis (84%), Tobacco (70%), Speed (26%), LSD (26%), Ecstasy (24%) Last month use only of common drugs – Alcohol (77%), Cannabis (61%), Tobacco (58%) Why do They Use It? Curiosity: to compare effects to cannabis (50%) Legal (39%) Easier to get than cannabis (23%) Recreational effects (20%) – Enjoyment, fun, relaxation, to ‘get high’ Alternative to cannabis (11%) Was offered in social situation (10%) Medicinal effects (9%) – Relief from pain, nausea, anxiety, insomnia To cease or reduce cannabis use (5%) Reasons for use - Drug testing 8% first
    [Show full text]
  • The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I
    STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I. Giancaspro, Nam-Cheol Kim, Jaap Venema, Susan de Mars, Jennifer Devine, Carlos Celestino, Christine E. Feaster, Ben A. Firschein, Mary S. Waddell, Stephen M. Gardner, and Earl Jones Jr.a ABSTRACT This Stimuli article analyzes the need for public quality standards for medical cannabis (defined herein as marijuana used for medical purposes under state laws) and the potential role of the U.S. Pharmacopeial Convention (USP) in addressing that need.1 Following legalization of the medical use of cannabis in several U.S. states and internationally, USP has received requests to investigate the advisability and feasibility of developing quality standards for medical cannabis. Development of quality standards for medical cannabis requires consideration of a wide range of scientific, legal, and policy issues that reach far beyond its classification as a botanical drug or herbal medicine. This article discusses the current regulatory and scientific landscape regarding medical cannabis, identifies issues related to the lack of quality standards for medical cannabis, and explores potential options for developing quality standards. USP seeks input from stakeholders on whether USP should proceed with development of quality standards for medical cannabis and if so, what approaches should be utilized to establish such standards. LEGAL AND REGULATORY LANDSCAPE The federal and state regulatory environment surrounding the medical use of cannabis involves many federal agencies and various different state laws. The evolving legal environment is an important consideration when evaluating the advisability and feasibility of USP developing a public standard for cannabis.
    [Show full text]
  • Therapeutic Aspects of Cannabis and Cannabinoids
    BRITISH JOURNAL OF PSYCHIATRY %2001), 178, 107^115 Therapeutic aspects of cannabis and cannabinoids{{ gave it to patients and was impressed with its muscle-relaxant, anticonvulsant and analgesic properties, and recorded its use- PHILIP ROBSON fulness as an anti-emetic. After these observations were published in 1842, medicinal use of cannabis ex- panded rapidly.It soon became available `over the counter' in pharmacies and by 1854 it had found its way into the United States Dispensatory.The American market became flooded with dozens of cannabis- containing home remedies. Background Review commissioned in In 1996 I was commissioned by the Depart- Queen Victoria's personal physician 1996 by the DepartmentofDepartment of Health ment of Health DOH) to review the wrote Reynolds, 1890), on the basis of scientific literature regarding the potential more than 30 years' experience, that DOH). therapeutic utility of cannabis and its ``Indian hemp, when pure and administered Aims Assess therapeutic profile of derivatives.The review was based upon carefully, is one of the most valuable primary sources identified from a Medline medicines we possess''.He found it incom- cannabis and cannabinoids. literature search, reference lists supplied by parable for ``senile insomnia'', ``night MethodMethod Medline search, references the DOH and the Institute for the Study of restlessness'' and ``temper disease'' in both Drug Dependence, and personal communi- children and adults, but not helpful in supplied by DOH and others, and cations with relevant academics
    [Show full text]
  • Medical Cannabis Template Policy 6-17-15
    Medical Cannabis Template Policy 6-17-15 Template 1- Will not allow Medical Cannabis in hospital (page 4): XXX Hospital recognizes that while Minnesota law permits Medical Cannabis for registered patients with a qualifying condition, medical cannabis will not be permitted in XXX Hospital Template 2a: Continue use as in-patient- Continuation of medical cannabis by patients – Self-Directed Therapy Arm (pages 5-6): XXX Hospital will permit the use of medical cannabis in a manner consistent with the registry program. XXX Hospital has exempted medical cannabis from its medication use policies and procedures. The policy provides guidance on the continuation of medical cannabis within XXX Hospital according to registry program. Only patients that hold Minnesota Department of Health (MDH) patient registration number will be permitted to use medical cannabis pursuant to this policy. Nothing in this policy should be interpreted to require health care practitioner to certify a patient as eligible for the registry program or to continue medical cannabis use as in-patient. Template 2b: Continue use as in-patient-Continuation of medical cannabis by patients- incorporated into medication process (pages 7-9): XXX Hospital will permit the use of medical cannabis in a manner consistent with the registry program. The policy provides guidance on the continuation of medical cannabis within XXX Hospital according to registry program. Only patients that hold Minnesota Department of Health (MDH) patient registration number will be permitted to use medical cannabis pursuant to this policy. Nothing in this policy should be interpreted to require a health care practitioner to certify a patient as eligible for the registry program or to continue medical cannabis use as in-patient.
    [Show full text]